진시스템
Financials
Valuation Metrics
진시스템's Market Cap is ₩354B. At end of 2025 it was ₩349B. Ranked #1908 of 2,410 in KR market (top 79%), #1188 of 1,631 on KOSDAQ (top 73%), #203 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 35.39B KRW | KR#1,908/2,410 Sec#203/231 |
| Revenue | 1.01B KRW | KR#2,376/2,410 Sec#218/231 |
| Net Income | -12.72B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 17.70B KRW | KR#2,376/2,410 Sec#227/231 |
| Net Assets | 11.65B KRW | KR#2,352/2,410 Sec#223/231 |
| Employees | 69 | KR#1,883/2,410 Sec#163/231 |
| Value | ||
| P/B | 3.04x | KR#2,159/2,410 Sec#175/231 |
| P/S | 35.04x | KR#2,358/2,410 Sec#195/231 |
| FCF Yield | -20.07% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -109.20% | KR#2,343/2,410 Sec#220/231 |
| ROA | -71.87% | KR#2,374/2,410 Sec#222/231 |
| Op. Margin | -777.39% | KR#2,364/2,410 Sec#210/231 |
| Revenue Growth | -4.59% | KR#1,746/2,410 Sec#167/231 |
| Financial Health | ||
| Debt Ratio | 51.95% | KR#981/2,410 Sec#115/231 |
| Total Debt | 3.72B KRW | KR#1,827/2,410 Sec#177/231 |
| FCF | -7.10B KRW | KR#1,592/2,410 Sec#133/231 |
| Cash | 4.06B KRW | KR#2,083/2,410 Sec#195/231 |
| Current Ratio | 3.59x | KR#440/2,410 Sec#67/231 |
| Performance | ||
| 1Y Return | -30.20% | KR#1,421/2,410 Sec#108/231 |
| 1M Return | -0.24% | KR#247/2,410 Sec#28/231 |
| From 52W High | -42.70% | KR#761/2,410 Sec#54/231 |
| 1Y MDD | -57.15% | KR#1,275/2,410 Sec#106/231 |
| Trading | ||
| Volume | 9,953 shares | KR#1,965/2,410 Sec#198/231 |
| Trading Value | 41.0M KRW | KR#1,923/2,410 Sec#202/231 |
| Foreign Own. | 0.96% | KR#2,044/2,410 Sec#200/231 |
| Per Share | ||
| EPS | -1,495 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,369 KRW | KR#2,225/2,410 Sec#197/231 |
Company Info
GeneSystem was established in 2010 to commercialize a rapid PCR technology-based platform and was listed on KOSDAQ in 2021. The company specializes in molecular diagnostic equipment and diagnostic kits, expanding its business primarily in Europe and Asia, and experienced growth in developing country markets post-2020 pandemic. It pursues market entry by diversifying rapid platform technology-based testing solutions and employing a two-track B2B strategy, continuously releasing respiratory disease diagnostic content for the post-COVID era to drive global market adoption. Headquartered in Yuseong-gu, Daejeon, GeneSystem was founded in 2010.